[1] HEIM MH, THIMME R. Innate and adaptive immune responses in HCV infections[J]. J Hepatol, 2014, 61 (1) :s14-s25.
|
[2] SHIMIZU K, SOROIDA Y, SATO M, et al. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter[J]. Sci Rep, 2018, 8 (1) :7845.
|
[3] SORESI M, TRIPI S, FRANCO V, et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis[J]. Liver Int, 2006, 26 (9) :1119-1125.
|
[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
[5] PFAFFL MW. A new mathematical model for relative quantification in real-time RT-PCR[J]. Nucleic Acids Res, 2001, 29 (9) :e45.
|
[6] LIVAK KJ, SCHMITTGEN TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T) ) method[J]. Methods, 2001, 25 (4) :402-408.
|
[7] ZHOU Y, YING L, XU JJ, et al. Effects of soluble human leukocyte antigen G on the standardized treatment of hepatitis C patients[J]. Chin J Clin Pharmacol Ther, 2018, 23 (7) :809-813. (in Chinese) 周勇, 应莉, 徐佳佳, 等.可溶性人类白细胞抗原G对丙型肝炎初治患者标准化治疗疗效的影响[J].中国临床药理学与治疗学, 2018, 23 (7) :809-813.
|
[8] CHENG DY, LIU XM, OU WN, et al. Clinical efficacy of directacting antiviral agents in patients with HCV-related liver cirrhosis[J/CD]. Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (6) :545-549. (in Chinese) 程丹颖, 刘晓民, 欧蔚妮, 等.直接抗病毒药物治疗丙型肝炎肝硬化患者的疗效观察[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (6) :545-549.
|
[9] MARTIN NK, VICKERMAN P, DORE GJ, et al. Comparing individual and population prevention benefits of early directacting antiviral treatment for HCV[J]. J Hepatol, 2016, 64 (2) :s464.
|
[10] LAVIE M, DUBUISSON J. Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly[J]. Biochimie, 2017, 141:62-69.
|
[11] KIM KH, HONG SP, KIM KJ, et al. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARγ[J].Biochem Biophys Res Commun, 2007, 355 (4) :883-888.
|
[12] TIAN Y, YANG Y, ZHANG X, et al. Age-dependent PPARαactivation induces hepatic sulfatide accumulation in transgenic mice carrying the hepatitis C virus core gene[J]. Glycoconj J, 2016, 33 (6) :927-936.
|
[13] MURTHY GD, VU K, VENUGOPAL S. Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection[J]. Eur J Gastroenterol Hepatol, 2009, 21 (8) :902-907.
|
[14] HSU CS, LIU CH, LIU CJ, et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype1 or 2 infection[J]. Am J Gastroenterol, 2009, 104 (3) :598.
|
[15] DAI CY, CHUANG WL, HO CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels:A community-based study[J]. J Hepatology, 2008, 49 (1) :9-16.
|
[16] COREY KE, KANE E, MUNROE C, et al. Hepatitis C virus infection and its clearance alter circulating lipids:Implications for long-term follow-up[J]. Hepatology, 2009, 50 (4) :1030-1037.
|
[17] MIRANDOLA S, BOWMAN D, HUSSAIN MM, et al. Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP) [J].Nutr Metab (Lond) , 2010, 7:13.
|
[18] TSAI TY, WANG WT, LI HK, et al. RNA helicase DDX3 maintains lipid homeostasis through upregulation of the microsomal triglyceride transfer protein by interacting with HNF4 and SHP[J]. Sci Rep, 2017, 7:41452.
|
[19] MOGILENKO DA, DIZHE EB, SHAVVA VS, et al. Role of the nuclear receptors HNF4α, PPARα, and LXRs in the TNFα-mediated inhibition of human apolipoprotein A-I gene expression in HepG2 cells[J]. Biochemistry, 2009, 48 (50) :11950-11960.
|